MX9700538A - Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares. - Google Patents

Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.

Info

Publication number
MX9700538A
MX9700538A MX9700538A MX9700538A MX9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A MX 9700538 A MX9700538 A MX 9700538A
Authority
MX
Mexico
Prior art keywords
droloxifene
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
MX9700538A
Other languages
English (en)
Inventor
Roland Loser
Michael Schliack
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9700538A publication Critical patent/MX9700538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

El uso de droloxifeno o una de sus sales farmacéuticamente aceptables en la preparacion de remedios para el tratamiento de enfermedades cardiovasculares.
MX9700538A 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares. MX9700538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,969 US5441986A (en) 1994-07-19 1994-07-19 Estrogen agonists as remedies for prostate and cardiovascular diseases
PCT/IB1995/000403 WO1996002242A1 (en) 1994-07-19 1995-05-26 Use of droloxifene for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
MX9700538A true MX9700538A (es) 1997-04-30

Family

ID=23058874

Family Applications (2)

Application Number Title Priority Date Filing Date
MX9700538A MX9700538A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
MX9700534A MX9700534A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX9700534A MX9700534A (es) 1994-07-19 1995-05-26 Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.

Country Status (17)

Country Link
US (4) US5441986A (es)
EP (3) EP1029540A3 (es)
JP (2) JPH09507859A (es)
KR (2) KR100212352B1 (es)
CN (2) CN1152868A (es)
AU (2) AU694220B2 (es)
CA (2) CA2195093C (es)
FI (2) FI970215A0 (es)
HK (1) HK1000697A1 (es)
HU (2) HUT77392A (es)
IL (2) IL114586A (es)
MX (2) MX9700538A (es)
MY (1) MY113079A (es)
NZ (2) NZ285159A (es)
TW (1) TW403649B (es)
WO (2) WO1996002242A1 (es)
ZA (2) ZA955963B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
HU230543B1 (hu) * 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
JP5123935B2 (ja) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
CA2677861C (en) * 2007-02-14 2015-05-19 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
FR2619383B1 (fr) * 1987-08-12 1989-12-08 Inst Vaisseaux Sang Proteine a activite vasculaire, derivee des monocytes et ses analogues, procede pour son extraction et leurs utilisations en therapeutique et pour la preparation d'anticorps
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases

Also Published As

Publication number Publication date
ZA955964B (en) 1997-01-20
HUT77391A (hu) 1998-04-28
CA2195093C (en) 2000-03-07
KR970704430A (ko) 1997-09-06
MY113079A (en) 2001-11-30
CA2195213A1 (en) 1996-02-01
FI970214A0 (fi) 1997-01-17
HU9700163D0 (en) 1997-03-28
FI970215A (fi) 1997-01-17
ZA955963B (en) 1997-01-20
EP1029540A2 (en) 2000-08-23
HK1000697A1 (en) 2002-05-10
WO1996002242A1 (en) 1996-02-01
FI970214A (fi) 1997-01-17
IL114585A0 (en) 1995-11-27
TW403649B (en) 2000-09-01
MX9700534A (es) 1997-04-30
EP1029540A3 (en) 2001-05-16
IL114586A0 (en) 1995-11-27
CN1153473A (zh) 1997-07-02
AU2417095A (en) 1996-02-16
FI970215A0 (fi) 1997-01-17
US5827892A (en) 1998-10-27
KR970704429A (ko) 1997-09-06
CN1152868A (zh) 1997-06-25
NZ285158A (en) 2000-07-28
HUT77392A (hu) 1998-04-28
KR100212352B1 (ko) 1999-08-02
HU9700162D0 (en) 1997-03-28
NZ285159A (en) 2000-10-27
EP0771194A1 (en) 1997-05-07
AU689257B2 (en) 1998-03-26
US5902830A (en) 1999-05-11
EP0769941A1 (en) 1997-05-02
CA2195093A1 (en) 1996-02-01
IL114586A (en) 2000-06-29
AU2416995A (en) 1996-02-16
KR100221854B1 (ko) 1999-09-15
WO1996002243A1 (en) 1996-02-01
CA2195213C (en) 2000-03-14
JPH09507860A (ja) 1997-08-12
JP2930424B2 (ja) 1999-08-03
AU694220B2 (en) 1998-07-16
JPH09507859A (ja) 1997-08-12
CN1076967C (zh) 2002-01-02
US5852059A (en) 1998-12-22
IL114585A (en) 2000-01-31
US5441986A (en) 1995-08-15

Similar Documents

Publication Publication Date Title
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
HU9603469D0 (en) Pyrazolo and pyrrolopyridines
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
AP9801392A0 (en) Concentrated antibody preparation.
PL316658A1 (en) Novel application of serotonin antagonists
FR2657259B1 (es)
ZA953256B (en) Skin treatment composition
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
ZA954984B (en) Compositions and methods for the treatment of tumors
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
MY113092A (en) Cisapride extended release
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
ZA952121B (en) Skin treatment composition
MX9700624A (es) Azolidinonas de imidazopiridina.
TR199501530A1 (tr) Osteoporoz tedavisinde terapötik döngüde kullanim icin kit.
GB9405046D0 (en) Skin treatment composition
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
HK1010095A1 (en) Use of 8,9-dehydroestrone for the manufacture of amedicament for the treatment of diseases caused byfree radicals.
EP0872219A4 (en) APPLICATION OF THE BIOFREQUENCY SPECT IN EMBYOTHECHNOLOGY IN ANIMALS
ZA9610264B (en) Preparation for use in the treatment of skin disorders.
GB9723824D0 (en) Cytostatic agents